Kodiak bags a $34M B round for retinal R&D

Kodiak CEO Victor Perlroth

Ophthalmology biotech Kodiak Sciences raised $34 million in Series B financing to speed up its pipeline of ocular therapies.

The company, founded in 2009, recruited an undisclosed U.S.-based investor to lead the round, earmarking funds for its work on an unnamed disease of the eye. With the fundraise, Kodiak has pulled in more than $60 million for its work, the company said.

Kodiak is keeping its targets under wraps as it works through preclinical studies, putting its new funds toward early-stage research as it develops new therapies for retinal disease.

"This financing is further recognition of the potential of our pipeline and platform in retina," CEO Victor Perlroth said in a statement. "We now move another step closer to our goal of building a long-term and independent retina franchise company for the benefit of patients."

- read the statement

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.